ASSOCIATION OF AMERICAN CANCER INSTITUTES

CME jointly provided by the American Association for Cancer Research and the Association of American Cancer Institutes.
Program Committee

**Chair:** Cornelia Ulrich, MS, PhD  
_Huntsman Cancer Institute_  
_University of Utah_

**Dario C. Altieri, MD**  
_Ellen and Ronald Caplan Cancer Center of The Wistar Institute_

**Julie Brabbs, MBA**  
_University of Michigan Rogel Cancer Center_

**David Darr, MSc, MBA**  
_Duke Cancer Institute_  
_Duke University Medical Center_

**Robert L. Ferris, MD, PhD**  
_UPMC Hillman Cancer Center_

**Wendy Law, PhD**  
_Fred Hutchinson Cancer Center_

**Caryn Lerman, PhD**  
_USC Norris Comprehensive Cancer Center_

**Ruben A. Mesa, MD, FACP**  
_Mays Cancer Center at UT Health San Antonio MD Anderson_

**Kunle Odunsi, MD, PhD**  
_The University of Chicago Medicine Comprehensive Cancer Center_

**Jennifer W. Pegher, MA**  
_Association of American Cancer Institutes_

**Jennifer Rogers, MBA**  
_UK Markey Cancer Center_

Meeting App and Social Media

The agenda, presentations, exhibitor information, and attendees list are available on the meeting app. To access the app:

- Download “Cvent Events” from your mobile app store.
- Log in with the name and email used during registration.
- You will receive a 6-digit verification code. Enter your code and log in.
- Within the Cvent Events app, search for “2022 AACI/CCAF Annual Meeting” and download the meeting. The meeting app can also be accessed on your desktop at: [https://cvent.me/3mAELl](https://cvent.me/3mAELl)

**Twitter:** @AACI_Cancer  
**Facebook:** AACICancer  
**Hashtag:** #AACI2022  
**Wireless Network:** IHG One Rewards Free Wi-Fi  
**Password:** AACI22
Welcome

I am delighted to welcome you to Kansas City for the 2022 AACI/CCAF Annual Meeting! This three-day meeting offers AACI members an opportunity to network with national cancer research and advocacy groups, industry, and government health agencies to develop solutions to common challenges.

I’d also like to extend a warm welcome to Koch Institute for Integrative Cancer Research at MIT and Houston Methodist Dr. Mary and Ron Neal Cancer Center, which bring our number of cancer center members to 105, and welcome Drs. Steven D. Leach, Kunle Odunsi, and Sarah Thayer to AACI’s Board of Directors. AACI extends its appreciation to outgoing board members, Drs. Carlos L. Arteaga, S. Gail Eckhardt, and Anil K. Rustgi.

We are pleased to recognize the research achievements of Dr. Elizabeth M. Jaffee with this year’s Distinguished Scientist Award. Dr. Jaffee will discuss current knowledge of precision immune oncology and novel clinical trial approaches under development. We will also honor Pelotonia with the AACI Champion for Cures Award in recognition of their philanthropic support of The Ohio State University Comprehensive Cancer Center. Dr. Electra Paskett will receive the AACI Cancer Health Equity Award in recognition of her exceptional leadership in promoting health equity and advocating for diversity and inclusion.

This year’s meeting program was jointly formulated by AACI and the Cancer Center Administrators Forum (CCAF). I would like to offer a special thanks to Dr. Cornelia Ulrich, who chaired the program committee. I would also like to thank Dr. Roy A. Jensen and The University of Kansas Cancer Center, for recommending the meeting location and connecting us with National World War I Museum and Memorial President and CEO Dr. Matthew Naylor, who will deliver the opening keynote. This meeting was three years in the making, and we are happy to welcome you back in person!

The program features panel discussions on topics including patient engagement and clinical trials; the evolution of the Cancer Moonshot program; precision oncology; and emerging from the COVID-19 pandemic. AACI President, Dr. Caryn Lerman, will provide an update on her presidential initiative, which is focused on diversifying the cancer leadership pipeline and preparing emerging leaders for advancement in their cancer centers. I am thankful for the hard work and expertise of the 2022 AACI/CCAF Annual Meeting Program Committee and AACI staff who helped make this meeting possible.

Sincerely,
Jennifer W. Pegher
Executive Director
**Agenda**

All sessions will be held in the Alameda Ballroom Salons I and II, except where indicated.

**Sunday, October 2**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:00 am</td>
<td><strong>Registration and Exhibits Open</strong></td>
<td>Ballroom Foyer</td>
</tr>
<tr>
<td>1:00 pm</td>
<td><strong>Welcome and AACI Business Meeting</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td><em>Dr. Caryn Lerman</em></td>
<td>USC Norris Comprehensive Cancer Center</td>
</tr>
<tr>
<td></td>
<td><em>Jennifer W. Pegher</em></td>
<td>Association of American Cancer Institutes</td>
</tr>
<tr>
<td></td>
<td><em>David M. Gosky</em></td>
<td>The Ohio State University Comprehensive Cancer Center</td>
</tr>
<tr>
<td></td>
<td><em>Julie Brabbs</em></td>
<td>University of Michigan Rogel Cancer Center</td>
</tr>
<tr>
<td></td>
<td><em>Dr. Cornelia Ulrich</em></td>
<td>Huntsman Cancer Institute, University of Utah</td>
</tr>
<tr>
<td>1:30 pm</td>
<td><strong>Opening Keynote: WWI Chemical Weapons and Chemotherapy</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>By the end of WWI, the use of chemical weapons had resulted in over 1,000,000 causalities on both sides, including many disabled and wounded. Through a series of unintended events these chemical weapons set in motion discoveries that led to the development of chemotherapy.</td>
<td></td>
</tr>
<tr>
<td></td>
<td><em>Dr. Matthew Naylor</em></td>
<td>National WWI Museum and Memorial</td>
</tr>
<tr>
<td>2:30 pm</td>
<td><strong>Networking Break</strong></td>
<td>Ballroom Foyer</td>
</tr>
<tr>
<td>3:00 pm</td>
<td><strong>Update on the NCI Cancer Centers Program</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Dr. Henry Ciolino will lead a discussion about the National Cancer Institute’s (NCI) goals for the national cancer research enterprise and provide updates on NCI funding at AACI cancer centers.</td>
<td></td>
</tr>
<tr>
<td></td>
<td><em>Dr. Henry Ciolino</em></td>
<td>National Cancer Institute</td>
</tr>
<tr>
<td>4:00 pm</td>
<td><strong>CCAF Business Meeting</strong> <em>(closed session for members of CCAF)</em></td>
<td>Alameda Ballroom Salon III</td>
</tr>
</tbody>
</table>
4:00 pm  **10th Annual AACI Physician Clinical Leadership Initiative (PCLI) Meeting: The Future of the Oncology Workforce With the Great Talent Swap**

More and more, cancer centers are faced with building desirable work cultures to retain faculty. Panelists will address factors impacting the ability of oncologists to build a successful career at an academic cancer center; the reasons physicians are migrating to industry; and how to measure the work of advanced practice providers and their support of physicians.

**Moderator: Dr. Claire Verschraegen**  
The Ohio State University Comprehensive Cancer Center

**Dr. Zoneddy Dayao**  
University of New Mexico Comprehensive Cancer Center

**Dr. Neal Meropol**  
Flatiron Health

**Dr. Ravi Parikh**  
Abramson Cancer Center of the University of Pennsylvania

5:30 – 7:30 pm  **Welcome Reception supported by Florence**

National WWI Museum and Memorial

Shuttles will depart the hotel beginning at 5:15 pm.

---

**Monday, October 3**

7:00 am  **Breakfast**  
The Rooftop Ballroom

7:00 am  **AACI Cancer Center Directors Breakfast**  
*(invitation only)*  
The Rooftop Bar

8:30 am  **AACI Presidential Initiative Update: Leadership Diversity and Development Initiative**

AACI President, Dr. Caryn Lerman, will provide an update on her presidential initiative, which focuses on leadership development with an emphasis on diversity. Discussion will include a toolkit of best practices for diversifying the leadership pipeline and a new workshop designed for current and emerging leaders at AACI cancer centers, to be held in November 2022.

**Dr. Caryn Lerman**  
USC Norris Comprehensive Cancer Center
Agenda

9:00 am  **NCI Director’s Report**

The acting director of the National Cancer Institute (NCI) will highlight programmatic priorities and identify funding opportunities to support ongoing collaborations between the NCI and academic cancer centers.

**Dr. Douglas Lowy**  
National Cancer Institute

10:00 am  **Leveraging Patient Engagement to Improve Clinical Trials**

Patient engagement is key to accelerating progress against cancer. However, many cancer centers have not tapped into this valuable resource. Panelists will discuss how patient input can make clinical trials more inclusive, improve telemedicine, and enhance community outreach and education. Other topics include the role of patient advocates on cancer center external advisory and community advisory boards and giving patients a “voice” on social media.

**Moderator: Dr. Ruben A. Mesa**  
Mays Cancer Center at UT Health San Antonio MD Anderson

**Dr. Marjory Charlot**  
UNC Lineberger Comprehensive Cancer Center  
University of North Carolina at Chapel Hill

**Hope Krebill**  
The University of Kansas Cancer Center

**Dina George Lansey**  
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University

11:00 am  **Coffee Break**  
Ballroom Foyer

11:15 am  **AACI Awards Presentation**

**2022 AACI Cancer Health Equity Award**

**Dr. Electra D. Paskett**  
The Ohio State University Comprehensive Cancer Center

**2022 AACI Champion for Cures Award**

**Pelotonia**  
The Ohio State University Comprehensive Cancer Center
11:30 am  **2022 AACI Distinguished Scientist Award**

**Progress in Converting Pancreatic Cancer Into an Immunologic Disease: Lessons Learned From the Clinic**

immune checkpoint inhibitors are providing durable clinical responses in about 20 percent of cancer patients with tumors that often express high mutational burdens. But these agents—both single and combination therapies—have minimal effect in low mutational burden cancers, which lack quality intratumoral T cells. This talk will discuss current knowledge of precision immune oncology and novel clinical trial approaches under development that show promise in bypassing one or more of the immune suppressive pathways.

**Dr. Elizabeth M. Jaffee**  
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University

---

12:30 pm  **Lunch**

Rooftop Ballroom

---

1:15 pm  **Networking Dessert**

Ballroom Foyer

---

1:45 pm  **AACI Clinical Research Innovation (CRI) Update**

In July, AACI's CRI convened its 14th annual meeting, “Partnering in Progress.” During this session panelists will share highlights of the meeting and provide an overview of recent CRI projects and their impact on cancer clinical trials.

**Dr. Thomas George, Jr.**  
University of Florida Health Cancer Center

**Dr. Christopher Lieu**  
University of Colorado Cancer Center

**Dr. Tara L. Lin**  
The University of Kansas Cancer Center

**Kristie Moffett**  
Moffitt Cancer Center

---

2:00 pm  **AACI Government Relations Forum**  
*(Session not CME accredited; pre-registration required)*

Rooftop Bar

The Government Relations Forum meeting provides an opportunity for attendees to engage with timely public policy topics. The meeting will feature compelling speakers from government, think tanks, and AACI cancer centers, and will allow time for discussion and networking.
Agenda

2:45 pm  **Cancer Center Perspectives on New NCI Guidelines**

The rapid evolution of cancer research and discovery requires persistent adjustments by cancer centers when responding to shifting funding criteria. New guidelines for the National Cancer Institute’s (NCI) Cancer Center Support Grant regarding community integration, consortia-planned enhanced diversity, and best practices for selecting centers to launch clinical trials will be considered in this session.

**Co-moderator: Dr. Dario C. Altieri**  
Ellen and Ronald Caplan Cancer Center of The Wistar Institute

**Co-moderator: Julie Brabbs**  
University of Michigan Rogel Cancer Center

**Dr. Richard Barakat**  
Northwell Health Cancer Institute

**Dr. Christopher Li**  
Fred Hutchinson Cancer Center

**Dr. Elena Martinez Stoffel**  
University of Michigan Rogel Cancer Center

3:45 pm  **Coffee Break**  
Ballroom Foyer

4:00 pm  **Concurrent Session**  
**Strategize and Collaborate: Tackling New Components of the CCSG**

NCI’s Cancer Center Support Grant (CCSG) guidelines are evolving with the times, perhaps most notably around efforts to enhance diversity at all levels of cancer center operations. Panelists from centers that have had recent experience with core grant submissions will engage in a conversation with audience members, focusing on new guidelines and how collaboration with other centers and better strategic planning can enhance preparation of a CCSG competing renewal.

**Moderator: Dr. Matthew Huesser**  
Sidney Kimmel Cancer Center at Jefferson Health

**Julie Brabbs**  
University of Michigan Rogel Cancer Center

**Peter Connor**  
University of Wisconsin Carbone Cancer Center

**Dr. Kimberly Kerstann**  
Winship Cancer Institute of Emory University

**Jennifer Rogers**  
UK Markey Cancer Center
4:00 pm  **Concurrent Session**

**Overview of the Basic Science Centers**
Alameda Ballroom Salon III

AACI’s basic science cancer center members focus on laboratory research and translate their findings into better cancer treatments. Directors from these centers will highlight innovative research discoveries that are accelerating progress against cancer.

**Moderator: Dr. Dario C. Altieri**
Ellen and Ronald Caplan Cancer Center of The Wistar Institute

**Dr. Rohit Bhargava**
Cancer Center at Illinois

**Dr. Reuben Shaw**
Salk Institute Cancer Center

**Dr. David Tuveson**
Cold Spring Harbor Laboratory Cancer Center

**Dr. Matthew Vander Heiden**
Koch Institute for Integrative Cancer Research at MIT

---

**8:30 – 10:30 PM**

**Hospitality** supported by Advarra
Rooftop Bar
## Agenda

**Tuesday, October 4**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:00 am</td>
<td>Breakfast</td>
<td>The Rooftop Ballroom</td>
</tr>
<tr>
<td>8:00 am</td>
<td><strong>A New Phase of the Cancer Moonshot</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>President Biden’s announcement of a renewed Cancer Moonshot has led to a sharper focus on prevention and screenings, along with efforts to address health disparities. Key players involved in the initiative will describe how the Moonshot program has transformed, and discuss ways in which the White House, National Cancer Institute, and our nation’s leading cancer centers can work together to “end cancer as we know it.”</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Co-moderator: Dr. Cornelia Ulrich</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Huntsman Cancer Institute, University of Utah</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Co-moderator: David Darr</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Duke Cancer Institute, Duke University Medical Center</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Dr. Danielle Carnival</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>White House Office of Science and Technology Policy</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Dr. Ruben A. Mesa</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Mays Cancer Center at UT Health San Antonio MD Anderson</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Dr. Dinah Singer</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>National Cancer Institute</td>
<td></td>
</tr>
<tr>
<td>9:00 am</td>
<td><strong>Drug Discovery and Development in Cancer Centers: Alternate Models and Drivers of Success</strong></td>
<td>Panelists will share how their centers successfully brought cancer drugs from bench to commercialization. Topics will include organoid models and advice for avoiding pitfalls in partnerships.</td>
</tr>
<tr>
<td></td>
<td><strong>Moderator: Dr. Kunle Odunsi</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>The University of Chicago Medicine Comprehensive Cancer Center</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Dr. Vasiliki Anest</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>USC Norris Comprehensive Cancer Center</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Dr. Michael Jackson</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Sanford Burnham Prebys Medical Discovery Institute</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Dr. Sanjay Malhotra</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>OHSU Knight Cancer Institute</td>
<td></td>
</tr>
</tbody>
</table>
10:00 am  **Coffee Break**  
Ballroom Foyer

10:15 am  **The Next Generation of Precision Oncology**
Preparation of the oncological ecosystem to realize the full potential of genomics-based precision medicine is an ongoing enterprise for the cancer center community. Panelists will examine approaches to moving precision medicine from bench to commercialization, including PDX models/organoid-based precision oncology, along with clinical implementation, precision prevention, and equity challenges.

**Co-moderator: Dr. Robert L. Ferris**  
UPMC Hillman Cancer Center

**Co-moderator: Dr. Wendy Law**  
Fred Hutchinson Cancer Center

**Dr. Luis Carvajal-Carmona**  
UC Davis Comprehensive Cancer Center

**Dr. Vinayak Prasad**  
University of California, San Francisco

**Dr. Alana Welm**  
Huntsman Cancer Institute, University of Utah

11:15 am  **Emerging From COVID-19**
After two years of unprecedented disruptions in cancer research and care caused by the COVID-19 pandemic, many cancer centers have developed creative solutions to a host of challenges including overextended staff, missed screenings, effective communication of scientific evidence, and training programs for the next generation of cancer researchers. Let’s learn from each other.

**Co-moderator: Dr. Steven Leach**  
Dartmouth Cancer Center, Dartmouth College

**Co-moderator: Dr. Wendy Law**  
Fred Hutchinson Cancer Center

**Dr. Marcia Cruz-Correa**  
University of Puerto Rico Comprehensive Cancer Center

**Sean Hobson**  
Dartmouth Cancer Center

**Dr. Anil K. Rustgi**  
Herbert Irving Comprehensive Cancer Center  
Columbia University Irving Medical Center

12:15 pm  **Adjourn**
Continuing Medical Education

Joint Providership Statement
Jointly provided by the American Association for Cancer Research (AACR) and the Association of American Cancer Institutes (AACI).

Accreditation
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AACR and AACI. AACR is accredited by the ACCME to provide continuing medical education (CME) for physicians.

Credit Designation Statement
AACR has designated this live activity for a maximum of 14.25 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Credit certification for individual sessions may vary, dependent upon compliance with the ACCME Accreditation Criteria. The final number of credits may vary from the maximum number indicated above.

Claiming CME Credit
Physicians and other health care professionals seeking AMA PRA Category 1 Credit(s)™ for this live continuing medical education activity must complete the online CME Request for Credit Survey by Thursday, November 17, 2022. Certificates will only be issued to those who complete the survey. The Request for Credit Survey will be available via a link on the conference website and via email. Your CME certificate will be sent to you via email after the completion of the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 14.25 Medical Knowledge points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

To receive ABIM MOC, participants must request MOC in the CME Request for Credit Survey and complete all questions. Once these steps are completed, AACR will submit your completion information via the ACCME’s Program and Activity Reporting System for the purpose of granting MOC points.

Statement of Educational Need, Target Audience, and Learning Objectives
Despite enormous progress in the field, cancer continues to be a global public health challenge, accounting for one in every six deaths that occur around the world. In the United States alone, it is predicted that more than 600,000 people will die from some form of cancer in 2022, making it the second most common cause of death after heart disease.
With the quickening pace of discoveries in basic, translational, and clinical research, the battle against cancer is rapidly moving forward. This is due in large part to the advent of new technologies, such as liquid biopsies, and our growing knowledge about how to activate the immune system to develop new immunotherapies. However, understanding and combating cancer requires leadership armed with up-to-date information about advanced technology and proven methods for its implementation.

Credit Designation Statement
AACR has designated this live activity for a maximum of 14.25 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Planned Goals and Objectives for the Education
Researchers, physicians, and other health care professionals who attend the meeting should be able to summarize the program content, discuss its application in clinical practice, and convey the information to faculty and staff at their cancer centers. As part of the program’s learning objectives, all attendees should be able to describe and discuss:

1. Engaging patients and their advocates in the development and conduct of cancer clinical trials
2. Research at basic science cancer centers
3. Creative solutions that cancer centers have developed in response to COVID-19 pandemic challenges
4. Compliance with current National Cancer Institute (NCI) Cancer Center Support Grant guidelines
5. Challenges and opportunities for collaboration among academia, government, and the private sector
6. Preparing the oncological ecosystem to realize the full potential of genomics-based precision medicine

Disclosure Statement
It is the policy of the AACR that the information presented at AACR CME activities will be unbiased and based on scientific evidence. To help participants make judgments about the presence of bias, AACR will provide information that Scientific Program Committee members and speakers have disclosed all financial relationships they have with ineligible companies whose primary business is producing, marketing, selling, reselling, or distributing health care products or services used by or on patients. All the relevant financial relationships for these individuals have been mitigated.

Acknowledgment of Financial or Other Support
This activity is supported by Professional Educational Grants and will be disclosed at the meeting.

Questions About CME?
Please contact the Office of CME at 215-440-9300 or cme@aacr.org.
2022 AACI Distinguished Scientist Award

Elizabeth M. Jaffee, MD
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University

Elizabeth M. Jaffee, MD, is the deputy director of the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University. A world leader in understanding the complex interaction between the immune system and pancreatic cancer, she led the direct translational development of a first-generation granulocyte-macrophage colony stimulating factor (GM-CSF)-secreting allogeneic vaccine platform that has served as a human model for studying anticancer immunity. Her ongoing work integrates new and emerging technologies to uncover the complex signaling pathways that exist between tumor cells, monocytes, and stromal cells in pancreatic cancer, and novel methods to bypass these signals to effect potent antitumor immune responses.

Dr. Jaffee was appointed by President Obama to serve on the National Cancer Advisory Board (NCAB). While chair of the NCAB, she served as one of three co-chairs of the Cancer Moonshot Blue Ribbon Panel, which established priorities for National Cancer Institute spending on new research. She continues to work with the Biden administration as a member of the President’s Cancer Panel. Dr. Jaffee also established the new Cancer Convergence Institute at the Kimmel Cancer Center at Johns Hopkins, where experts from diverse fields such as engineering, bioinformatics, physics, and mathematics work with doctors and nurses to apply their knowledge to cancer.

Recent AACI Distinguished Scientist honorees include Drs. Judy E. Garber; William G. Kaelin, Jr.; Douglas R. Lowy; Charles Perou; Carl June; James Allison; and Lewis Cantley.
Pelotonia

In its first 13 years, Pelotonia—a three-day experience of cycling, entertainment, and volunteerism—has raised more than $236 million for The Ohio State University Comprehensive Cancer Center. The dollars raised support projects that address many areas of cancer research, including prevention, diagnosis, treatment, psychosocial issues, accelerated drug development and large initiatives that help change the landscape of cancer care.

The Ohio State University Comprehensive Cancer Center has dedicated these funds to building innovative programs and initiatives, such as the Pelotonia Fellowship Program and the Pelotonia Idea Grants Program. Through a five-year pledge of $100 million, Pelotonia will launch an institute for immuno-oncology at the cancer center. The center has also used funds raised by Pelotonia to support four state-wide initiatives on colorectal cancer prevention, the prevention and treatment of endometrial cancer, assessing survival and quality of life using genetic testing for advanced stage lung cancer, and reducing the high breast cancer mortality among African American women in Ohio.

The Champion for Cures Award was established as an annual award in 2018 to recognize philanthropic support of AACI cancer centers.
Electra D. Paskett, PhD, is the associate director for population sciences and community outreach and founding director of the Center for Cancer Health Equity (CCHE) at The Ohio State University Comprehensive Cancer Center. Dr. Paskett has led multi-disciplinary teams of investigators in several large initiatives to understand and reduce disparities within the cancer center’s catchment area. These roles have afforded her the opportunity to train the next generation of investigators—from high school to junior faculty—in health disparities, diversity, and inclusion.

Established in 2002 with a focus on increasing accrual to clinical trials among minorities, the CCHE has grown from three to 17 staff members, with dedicated staff representing minority, rural, and Appalachian population groups in Ohio. CCHE initiatives are focused on education and outreach to these populations; direct services, such as mobile mammography; and Continuum of Care Navigation. In addition, Dr. Paskett directs a 10-week Summer Health Disparities Program for undergraduate, graduate, and medical students, including those from historically Black colleges and universities. Many of the 65 past students have gone on to careers in science.

Dr. Paskett has extended her leadership through her service as past president of the American Society of Preventive Oncology and as a member of many committees of the American Society of Clinical Oncology, the American Cancer Society, and the American Association of Cancer Research. She is also a member of the Ohio Commission on Minority Health and the National Cancer Institute’s National Cancer Advisory Board.

The Cancer Health Equity Award was established as an annual award in 2021 to recognize exceptional leadership in promoting health equity, mitigating cancer disparities, and advocating for diversity and inclusion.
By the end of World War I, the use of chemical weapons had resulted in over 1,000,000 casualties on both sides, including many disabled and wounded. Through a series of unintended events, these chemical weapons set in motion discoveries that led to the development of chemotherapy.

Following the war, medical researchers noticed that mustard gas destroyed lymphatic tissue and bone marrow, leading them to experiment with applying nitrogen mustard, a derivative of mustard gas, to shrink tumors in mice.

By the beginning of World War II in the early 1940s, the first therapeutic experiments with the intravenous use of mustard agents were conducted in patients with cancer, providing temporary benefit. Several drugs derived from mustard agents are still used today to treat certain forms of cancer.

Matthew Naylor, PhD, president and CEO of the National WWI Museum and Memorial, will describe these discoveries and their impact on modern cancer treatment during the opening keynote.

A native of Australia with more than 30 years of nonprofit leadership experience, Dr. Naylor began his tenure at the museum and memorial in June 2013. In 2018, Dr. Naylor was named Nonprofit PRO "Executive of the Year" and in 2019, Ingram’s Magazine included him on its "50 Missourians You Should Know" list. He serves on boards and committees for several civic and educational initiatives, including the advisory council for the Kansas City Economic Development Corporation, the advisory board for the National Stars and Stripes Museum, and the board of the Institute for Sustainable Philanthropy.
The American Association for Cancer Research (AACR) and the Association of American Cancer Institutes (AACI) express appreciation to the following companies for their support of this educational activity by providing exhibit fees:

**Advarra**
Advarra advances the way clinical research is conducted: bringing life sciences companies, CROs, research sites, investigators, and academia together at the intersection of safety, technology, and collaboration. With trusted IRB and IBC review solutions, innovative technologies, experienced consultants, and deep-seated connections across the industry, Advarra provides integrated solutions that safeguard trial participants, empower clinical sites, ensure compliance, and optimize research performance. Advarra is advancing clinical trials to make them safer, smarter, and faster. Learn more about our cloud-based technology solutions, IBC and IRB services, Institutional Research Center of Excellence, and professional services. For more information, visit [advarra.com](http://advarra.com).

**Caris Life Sciences®**
Caris Life Sciences® is a leading innovator in molecular science focused on fulfilling the promise of precision medicine through quality and innovation. The company’s suite of market-leading molecular profiling offerings assess DNA, RNA, and proteins to reveal a molecular blueprint that helps physicians and cancer patients make more precise and personalized treatment decisions. Headquartered in Irving, Texas, Caris Life Sciences offers services throughout the U.S., Europe, Asia, and other international markets. To learn more, please visit [CarisLifeSciences.com](http://CarisLifeSciences.com) or follow us on Twitter (@CarisLS).

**Deep 6 AI**
Deep 6 AI is the leader in precision research software, connecting all research stakeholders in an AI-powered, real-time, data-driven, collaborative ecosystem. Our Precision Matching software mines millions of patient records, including “unstructured” physician notes, to pinpoint eligible study patients in real time. Deep 6 AI eliminates months of manual data validation, to de-risk and accelerate clinical trials, because clinical trials should be a gatekeeper (accelerator), not a bottleneck to innovation. [deep6ai](http://deep6ai)

**ECG Management Consultants, a Siemens Healthineers Company**
With knowledge and expertise built over the course of nearly 50 years, ECG is a national consulting firm that is leading health care forward. ECG offers a broad range of strategic, financial, operational, and technology-related consulting services to providers, building multidisciplinary teams to meet each client’s unique needs – from discrete operational issues to bigger-picture strategic and financial challenges. ECG is an industry leader, offering specialized expertise to hospitals, health systems, medical groups, academic medical centers, children’s hospitals, ambulatory surgery centers, and health care payers. Part of Siemens Healthineers’ global enterprise services practice, ECG’s subject matter experts deliver smart counsel and pragmatic solutions. [ecgmc.com](http://ecgmc.com)
**Florence**
Florence is the leading platform for remote connectivity and electronic document workflow management in clinical research. It is considered the industry standard, with more than 12,000 research sites, sponsors, and CROs in 45 countries collaborating on its network. Florence advances clinical trials through software for managing document and data flow between research sites and sponsors. Florence solutions foster 25 percent faster start-up time and 40 percent reduced document cycle time, among other benefits. To learn about advancing research through collaboration, visit florencehc.com.

**Huron**
Huron’s cancer center team is composed of leaders with 20-plus years of frontline experience in academic-based cancer centers. They rely on their firsthand knowledge of best practices to help improve your center’s performance across multiple dimensions, tailoring approaches and solutions to your center’s goals, issues, and organizational environment. Our team has worked with over 75 aspiring and established cancer centers, notably assisting institutions in renewing or obtaining their first National Cancer Institute designation award and designing a statewide, multi-institutional organizational structure for conducting clinical trials. We have extensive experience in the clinical research, clinical trials, and biotechnology spaces, spurring innovation and advancing knowledge. huronconsultinggroup.com

**Inspirata**
Inspirata, Inc. helps patients fighting cancer—and the clinicians they trust—to make every moment matter. We are a Cancer Informatics company that offers several innovative software solutions leveraging scalable AI and NLP in the clinical trial and cancer registry spaces. Refined over more than a decade in collaboration with the National Cancer Institute and used by hundreds of health care institutions globally, our proprietary NLP engine is at the heart of Nurse Navigator and Trial Navigator, our powerful clinical trial matching solutions, and our industry-leading E-Path suite of cancer registry automation solutions. inspirata.com

**Merck**
At Merck, our goal is to translate breakthrough science into innovative oncology medicines to help people with cancer. The potential to bring new hope to people with cancer drives our purpose and our commitment. As part of our focus on cancer, Merck is committed to clinical research with one of the largest development programs in the industry across more than 30 tumor types. merck.com
nCoup*

nCoup provides innovative cloud solutions that address operational needs of organizations conducting clinical research. nCoup recently launched nCartes, the next generation EHR to EDC clinical data transport platform that enables sites and sponsors to harness electronic medical records to populate EDC systems and fulfill clinical trials. nCartes has been proven to reduce the time and cost of data entry on some cancer clinical trials by 50 percent. nCoup leverages its extensive and deep EHR integration and clinical trials software expertise to deliver nCartes. nCoup, Inc. is privately held with headquarters in Fremont, California. For more information on nCoup, please visit ncoup.com. For more information on nCartes, please visit ncartes.ncoup.com.

Patient Resource

Patient Resource is a market differentiator. Providing personal touchpoints throughout each person’s continuum of care builds a lifelong relationship between the cancer center and the patient and their loved ones. The educational and emotional support you can provide your patients through this tool is unparalleled. And, from a business perspective, it’s a strong patient acquisition/retention program. navigator.patientresource.com

Servier

As a growing leader in oncology, Servier is committed to finding solutions that will address today's challenges. The company's oncology portfolio of innovative medicines is designed to bring more life-saving treatments to a greater number of patients, across the entire spectrum of disease and in a variety of tumor types. Currently, we have four medicines approved in acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML) and cholangiocarcinoma (CCA). We have also accelerated our investment in hard-to-treat cancers, with more than 50 percent of research and development dedicated to oncology. Our goal is to serve our patients with the utmost treatment and care to improve the potential for survival. servier.com

Takeda Oncology

At Takeda Oncology, we aspire to cure cancer, with inspiration from patients and innovation from everywhere. We ensure a tight connection from research to development to commercialization to meet the needs of the cancer community, optimizing our ability to bring potentially transformative medicines to patients. Our demonstrated leadership in the treatment of hematologic cancers and solid tumors, combined with cutting-edge science through multiple platforms, partnerships, and therapeutic approaches, enables us to bring novel medicines to patients worldwide. takedaoncology.com

* virtual only
**TriNetX**
TriNetX is a global network of health care organizations and life sciences companies driving real-world research to accelerate the development of new therapies. Through its self-service, HIPAA-, GDPR-, and LGPD-compliant platform of federated EHR, datasets, and consulting partnerships, TriNetX puts the power of real-world data into the hands of its worldwide community to improve protocol design, streamline trial operations, refine safety signals, and enrich real-world evidence generation. trinetx.com

**Triomics**
Triomics is a technology company that enables site staff to directly transfer data to/from EHRs, labs, medical devices, and other sources directly into both sponsors’ and investigators’ EDC of choice. In addition, Triomics provides a full-stack platform for sites to initiate and manage clinical studies, right from study activation, patient recruitment, and engagement to study finance; thus, helping sites save time and resources usually spent on double data entry, SDV with monitors, identifying patients, and managing study expenses. What’s more, Triomics provides its technology stack free of cost to the sites and always will. triomics.com

**Verily**
Verily is an Alphabet company that combines a data-driven, people-first approach to bring the promise of precision health to everyone, every day. Within Verily, the Clinical Studies Platforms organization provides solutions to generate the data and evidence needed to inform critical treatment and care decisions. This function evolved from Project Baseline, a multi-year research initiative, and is composed of leading experts in clinical science, RWD and RWE, technology, and user experience. The team delivers research-ready datasets that bring together a wide variety of different sources of health data to represent the longitudinal health journey of individuals. To do this, Verily focuses on understanding permissions, enabling traceability, and solving for markedly different data integrity and quality.

Our solutions bring together evidence generation, care delivery, and care management in a connected and reinforcing ecosystem built to advance precision health, connecting research participants with studies and offering tools to improve clinical research. This includes SignalPath, a new state-of-the-art clinical trial management system (CTMS) that was built by researchers, for researchers, to dramatically improve the ease, quality, efficiency, and profitability of trial execution. verily.com
Exhibitors

WellSky®
WellSky Biotherapies enhances the donor and patient experience, simplifies resource management, tracks clinical trials through post-transplant follow-up, and shares individualized treatment outcomes with key stakeholders. WellSky is best positioned to meet the allogeneic and autologous supply chain management needs of blood and marrow transplant programs, cell processing labs, research and manufacturing organizations, independent biobanks and repositories, and cord blood and tissue banks. Health Care Software Solutions | WellSky®

YUNU, Inc.
Yunu provides medical research technology and services to life sciences companies and clinical research environments that perform precision imaging assessments. Yunu’s aim is to ensure breakthrough therapies are accessible to everyone by unifying medical imaging insights and connecting clinical communities. With thousands of clinical trials relying on the platform each day, Yunu is delivering a new standard of oncology trial management. yunu.io
Support

Acknowledgment of Commercial Support

The American Association for Cancer Research (AACR) and the Association of American Cancer Institutes (AACI) express appreciation to the following companies for their support of this educational activity by providing an unrestricted educational grant:

- AbbVie
- Gilead
- GlaxoSmithKline (GSK)
- Janssen
- Novartis
- Varian Medical Systems

Acknowledgment of Programmatic Support

AACI gratefully acknowledges the following organizations for providing program and exhibit support:

- Advarra
- Caris Life Sciences®
- Deep 6 AI
- ECG Management Consultants, a Siemens Healthineers Company
- Florence
- Huron
- Inspirata
- Merck
- nCoup
- Patient Resource
- Servier
- Takeda
- TriNetX
- Triomics
- Verily
- WellSky
- YUNU, Inc.

Support as of September 28, 2022
### CME-Approved Sessions Worksheet

<table>
<thead>
<tr>
<th>Date</th>
<th>Time</th>
<th>Session Title</th>
<th>Approved Credits</th>
<th>Credits Claimed</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Sunday 10/2/2022</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1:30 – 2:30 pm</td>
<td>Opening Keynote : WWI Chemical Weapons and Chemotherapy</td>
<td>1.0</td>
<td></td>
<td></td>
</tr>
<tr>
<td>3:00 – 4:00 pm</td>
<td>Update on the NCI Cancer Centers Program</td>
<td>1.0</td>
<td></td>
<td></td>
</tr>
<tr>
<td>4:00 – 5:30 pm</td>
<td>10th Annual AACI Physician Clinical Leadership Initiative (PCLI) Meeting: The Future of the Oncology Workforce With the Great Talent Swap</td>
<td>1.5</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Maximum Approved Credits for 10/2/22**: 3.5 **Total:**

| **Monday 10/3/2022** |               |                                                                              |                  |                 |
| 8:30 – 9:00 am       | AACI Presidential Initiative Update: Leadership Diversity and Development Initiative | 0.5              |                 |
| 9:00 – 10:00 am      | NCI Director’s Report                                             | 1.0              |                 |
| 10:00 – 11:00 am     | Leveraging Patient Engagement to Improve Clinical Trials           | 1.0              |                 |
| 11:30 am – 12:30 pm  | 2022 AACI Distinguished Scientist Award                           | 1.0              |                 |
| 1:45 – 2:45 pm       | AACI Clinical Research Innovation (CRI) Update                    | 1.0              |                 |
| 2:45 – 3:45 pm       | Cancer Center Perspectives on New NCI Guidelines                  | 1.0              |                 |
| 4:00 – 5:15 pm       | Overview of the Basic Science Cancer Centers                     | 1.25             |                 |
|                       | Strategize and Collaborate: Tackling New Components of the CCSG  |                   |                 |

**Maximum Approved Credits for 10/3/22**: 6.75 **Total:**

| **Tuesday 10/4/2022** |               |                                                                              |                  |                 |
| 8:00 – 9:00 am        | A New Phase of the Cancer Moonshot                                | 1.0              |                 |
| 9:00 – 10:00 am       | Drug Discovery and Development in Cancer Centers: Alternate Models and Drivers of Success | 1.0              |                 |
| 10:15 – 11:15 am      | The Next Generation of Precision Oncology                         | 1.0              |                 |
| 11:15 am – 12:15 pm   | Emerging From COVID-19                                            | 1.0              |                 |

**Maximum Approved Credits for 10/4/22**: 4.0 **Total:**

**Maximum CME Credits Approved**: 14.25 **Total:**
<table>
<thead>
<tr>
<th>Last Name</th>
<th>First Name</th>
<th>Relationships</th>
<th>Type</th>
<th>Role</th>
</tr>
</thead>
<tbody>
<tr>
<td>Altieri</td>
<td>Dario</td>
<td>No Relationships</td>
<td></td>
<td>Program Committee, Speaker</td>
</tr>
<tr>
<td>Anest</td>
<td>Vasiliki</td>
<td>No Relationships</td>
<td></td>
<td>Speaker</td>
</tr>
<tr>
<td>Barakat</td>
<td>Richard</td>
<td>No Relationships</td>
<td></td>
<td>Speaker</td>
</tr>
<tr>
<td>Bhargava</td>
<td>Rohit</td>
<td>No Relationships</td>
<td></td>
<td>Speaker</td>
</tr>
<tr>
<td>Brabbs</td>
<td>Julie</td>
<td>No Relationships</td>
<td></td>
<td>Program Committee, Speaker</td>
</tr>
<tr>
<td>Carnival</td>
<td>Danielle</td>
<td>No Relationships</td>
<td></td>
<td>Speaker</td>
</tr>
<tr>
<td>Carvajal-Carmona</td>
<td>Luis</td>
<td>No Relationships</td>
<td></td>
<td>Speaker</td>
</tr>
<tr>
<td>Charlot</td>
<td>Margot</td>
<td>No Relationships</td>
<td></td>
<td>Speaker</td>
</tr>
<tr>
<td>Ciolino</td>
<td>Henry</td>
<td>No Relationships</td>
<td></td>
<td>Speaker</td>
</tr>
<tr>
<td>Connor</td>
<td>Peter</td>
<td>No Relationships</td>
<td></td>
<td>Speaker</td>
</tr>
<tr>
<td>Cruz-Correa</td>
<td>Marcia</td>
<td>PCOT, Pfizer, Janssen, AbbVie, Taiho, Merck, BMS</td>
<td>S, GC, OBO</td>
<td>Speaker</td>
</tr>
<tr>
<td>Darr</td>
<td>David</td>
<td>No Relationships</td>
<td></td>
<td>Program Committee, Speaker</td>
</tr>
<tr>
<td>Dayao</td>
<td>Zoneddy</td>
<td>Gilead Sciences, Biotheranostics</td>
<td>O</td>
<td>Speaker</td>
</tr>
<tr>
<td>Ferris</td>
<td>Robert</td>
<td>Adagene Incorporated; Aduro Biotech; AstraZeneca; Bicara Therapeutics, Inc.; BMS; Brooklyn Immunotherapy; Catenion; Coherus BioSciences; EMD Serono; Everest Clinical Research Corporation; F. Hoffmann-La Roche Ltd.; Federation Bio, Inc.; Genocea Biosciences, Inc.; Hookipa Biotech GmbH; Instil Bio, Inc.; Kowa Research Institute Inc.; Lifestsciences Dynamics Limited; MacroGenics, Inc.; MeiraGTx, LLC; Merck; Mirati Therapeutics, Inc.; Mirror Biologics, Inc.; Nanobiotix; Novartis Pharmaceutical Corporation; Novasenta; Numab Therapeutics AG; OncoCyte Corporation; Pfizer; PPD Development, L.P.; Rakuten Medical, Inc.; Sanofi; Seagen; SIRPant Immunotherapeutics, Inc.; Tesaro; Vir Biotechnology; Zymeworks</td>
<td>IC, S, O</td>
<td>Program Committee, Speaker</td>
</tr>
<tr>
<td>George</td>
<td>Thomas</td>
<td>Pfizer Oncology; Tempus Labs, Inc.</td>
<td>IC</td>
<td>Speaker</td>
</tr>
<tr>
<td>Hobson</td>
<td>Sean</td>
<td>No Relationships</td>
<td></td>
<td>Speaker</td>
</tr>
<tr>
<td>Huegger</td>
<td>Matthew</td>
<td>No Relationships</td>
<td></td>
<td>Speaker</td>
</tr>
<tr>
<td>Jackson</td>
<td>Michael</td>
<td>No Relationships</td>
<td></td>
<td>Speaker</td>
</tr>
<tr>
<td>Jaffee</td>
<td>Elizabeth</td>
<td>Abmeta, Genocea, Achilles, Dragonfly Tx, NextCure, Parker Institute, Lustgarten, BTC, Carta, Genentech, AstraZeneca</td>
<td>O, GC</td>
<td>Speaker</td>
</tr>
<tr>
<td>Kerstann</td>
<td>Kimberly</td>
<td>No Relationships</td>
<td></td>
<td>Speaker</td>
</tr>
<tr>
<td>Krebell</td>
<td>Hope</td>
<td>No Relationships</td>
<td></td>
<td>Speaker</td>
</tr>
<tr>
<td>Lansey</td>
<td>Dina George</td>
<td>No Relationships</td>
<td></td>
<td>Speaker</td>
</tr>
<tr>
<td>Law</td>
<td>Wendy</td>
<td>No Relationships</td>
<td></td>
<td>Program Committee, Speaker</td>
</tr>
</tbody>
</table>
In compliance with the standards set by the Accreditation Council for Continuing Medical Education (ACCME), it is the policy of the American Association for Cancer Research (AACR) that the information presented at CME activities will be unbiased and based on scientific evidence. To help participants make judgments about the presence of bias, the AACR has provided information that planning committee members, speakers, and abstract presenters have disclosed about financial relationships they have with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing health care products or services used by or on patients.

<table>
<thead>
<tr>
<th>Last Name</th>
<th>First Name</th>
<th>Relationships</th>
<th>Type</th>
<th>Role</th>
</tr>
</thead>
<tbody>
<tr>
<td>Leach</td>
<td>Steven</td>
<td>No Relationships</td>
<td></td>
<td>Speaker</td>
</tr>
<tr>
<td>Lerman</td>
<td>Caryn</td>
<td>No Relationships</td>
<td></td>
<td>Program Committee, Speaker</td>
</tr>
<tr>
<td>Li</td>
<td>Christopher</td>
<td>No Relationships</td>
<td></td>
<td>Speaker</td>
</tr>
<tr>
<td>Lieu</td>
<td>Christopher</td>
<td>Merck, Natera</td>
<td>GC, O</td>
<td>Speaker</td>
</tr>
<tr>
<td>Lin</td>
<td>Tara</td>
<td>No Relationships</td>
<td></td>
<td>Speaker</td>
</tr>
<tr>
<td>Lowy</td>
<td>Douglas</td>
<td>Merck, GlaxoSmithKline</td>
<td>P</td>
<td>Speaker</td>
</tr>
<tr>
<td>Malhotra</td>
<td>Sanjay</td>
<td>Cadila Pharmaceuticals Ltd.</td>
<td>O</td>
<td>Speaker</td>
</tr>
<tr>
<td>Meropol</td>
<td>Neal</td>
<td>Flatiron Health, Roche</td>
<td>E, O</td>
<td>Speaker</td>
</tr>
<tr>
<td>Mesa</td>
<td>Ruben</td>
<td>Incyte, BMS, CTI, Sierra Oncology, Novartis, AbbVie, Imago, Blueprint</td>
<td>IC, GC</td>
<td>Program Committee, Speaker</td>
</tr>
<tr>
<td>Moffett</td>
<td>Kristie</td>
<td>No Relationships</td>
<td></td>
<td>Speaker</td>
</tr>
<tr>
<td>Naylor</td>
<td>Matthew</td>
<td>Cerner</td>
<td>O</td>
<td>Speaker</td>
</tr>
<tr>
<td>Odunsi</td>
<td>Kunle</td>
<td>No Relationships</td>
<td></td>
<td>Program Committee, Speaker</td>
</tr>
<tr>
<td>Parikh</td>
<td>Ravi</td>
<td>Humana, Thyme Care, Merck</td>
<td>IC, GC, SO, S</td>
<td>Speaker</td>
</tr>
<tr>
<td>Paskett</td>
<td>Electra</td>
<td>Pfizer, Merck Foundation, Genentech, Guardant Health</td>
<td>GC</td>
<td>Speaker</td>
</tr>
<tr>
<td>Pegher</td>
<td>Jennifer</td>
<td>No Relationships</td>
<td></td>
<td>Program Committee, Speaker</td>
</tr>
<tr>
<td>Prasad</td>
<td>Vinayak</td>
<td>Arnold Ventures, Johns Hopkins Press, Medscape, MedPage, UnitedHealthcare, OptumRx</td>
<td>GC, O</td>
<td>Speaker</td>
</tr>
<tr>
<td>Rogers</td>
<td>Jennifer</td>
<td>No Relationships</td>
<td></td>
<td>Program Committee, Speaker</td>
</tr>
<tr>
<td>Rustgi</td>
<td>Anil</td>
<td>No Relationships</td>
<td></td>
<td>Speaker</td>
</tr>
<tr>
<td>Shaw</td>
<td>Reuben</td>
<td>No Relationships</td>
<td></td>
<td>Speaker</td>
</tr>
<tr>
<td>Singer</td>
<td>Dinah</td>
<td>No Relationships</td>
<td></td>
<td>Speaker</td>
</tr>
<tr>
<td>Stoffel</td>
<td>Elena Martinez</td>
<td>No Relationships</td>
<td></td>
<td>Speaker</td>
</tr>
<tr>
<td>Tuveson</td>
<td>David</td>
<td>Surface Oncology, Leap Therapeutics, Sonata, Mestag Therapeutics, XiIs</td>
<td>SO, S</td>
<td>Speaker</td>
</tr>
<tr>
<td>Ulrich</td>
<td>Cornelia</td>
<td>No Relationships</td>
<td></td>
<td>Program Committee, Speaker</td>
</tr>
<tr>
<td>VanderHeiden</td>
<td>Matthew</td>
<td>Agios, iTeos, Sage, Auron, Fateh, Drioa Ventures</td>
<td>SO, O</td>
<td>Speaker</td>
</tr>
<tr>
<td>Verschraegen</td>
<td>Claire</td>
<td>No Relationships</td>
<td></td>
<td>Speaker</td>
</tr>
<tr>
<td>Welm</td>
<td>Alana</td>
<td>No Relationships</td>
<td></td>
<td>Speaker</td>
</tr>
</tbody>
</table>

All of the relevant financial relationships listed for these individuals have been mitigated.
You have patient safety, drug accountability, protocols, investigator satisfaction, team management, grants, NCI designations, training, and a million things to think about when managing research operations and accelerating cures. Your regulatory and source documentation shouldn’t be one of them.

Florence helps you, numerous AACI member institutes, and more than 8,500 study sites in 34 countries, optimize electronic document workflows and enable remote site access.

Learn more and see stories of other institutes using Florence to accelerate research.

FlorenceStories.com
The Deep 6 AI platform connects all research stakeholders in a real-time, data-driven, collaborative ecosystem.

- Search through unstructured data in minutes, eliminating months of manual screening
- Attract more sponsored studies to turn your site into a profit center
- Increase diversity by expanding trial access to your site’s entire patient population

Stop by our booth to enter TUMI suitcase giveaway
Cancer Care Is Under Pressure

ECG's payer strategies and operations expertise help cancer centers optimize financial performance and protect patient care.

To learn more visit ecgmc.com/cancer or call 1(800) 729-7635
Huron understands cancer centers.

Addressing the unique needs of the world's leading cancer centers:

- Enhance clinical research operations.
- Streamline research administration.
- Provide strategic advice.
- Prepare for National Cancer Institute

huronconsultinggroup.com/insights/strategic-solutions-cancer-centers

© 2022 Huron Consulting Group Inc. and affiliates. 2022

PATIENT RESOURCE NAVIGATOR

Empower Patients
Increase Referrals
Grow Market Share

90% of patients who receive Patient Resource Guides recommend their cancer center to others

Navigator.PatientResource.com
Contact Amy Galey to learn more
agaley@patientresource.com / 913-725-1632

Visit us at AACI/CCAF Annual Meeting
Study site performance made easy

Time to reimagine research. Learn how study sites can simplify management of a complex portfolio of studies with SignalPath CTMS.

Empower optimal performance
Maximize research revenue
Integrate and unify solutions

To learn more, visit us at verily.com/signalpath

Streamline recruiting & patient scheduling, access data across multiple studies, and make quicker decisions with real-time analytics using WellSky® Biotherapies

Learn more
Join the Yuniverse
Become part of a global community leading innovation in cancer care

yunu.io

2023 AACI/CCAF ANNUAL MEETING
October 1-3, 2023
Salamander Washington DC
(formerly Mandarin Oriental, DC)